Email & Chat Correspondence

Incoming Emails

Email from: dr.ramos@cedarfieldclinic.org
Subject: Pre-Order Request for Study — April 4, 2025
Hello Pentovil Team, I’m writing to express interest in acquiring a pre-trial batch of Pentovil Penatrailin for internal study at Cedarfield Psychiatric. We are currently onboarding six patients under Category-III trauma-linked dissociation. Please advise on bulk ordering process. Regards, Dr. L. Ramos Cedarfield Clinic, Maryland
Email from: jkoray@neuronetlabs.ca
Subject: RE: Limited Distribution? — April 12, 2025
Hi again, We submitted the grant application to the Canadian Registry for Ethical Neuropharmacology (CREN) and are awaiting approval. Meanwhile, could we secure two sample vials for microdosing trials? We suspect the compound has off-label potential for dream-cycle stabilization. Thanks in advance, J. Koray Neuropath Integration Labs, Ontario
Email from: anonymous_unifiednet@protonmail.com
Subject: They're asking for it again — April 17, 2025
You shouldn't have brought it back. The last time they used it, people vanished and no one reported it. Stop shipping to Oklahoma. You know why. - Zero is listening.

Internal Chat Logs

[04/19/25 — 11:22AM] Anderson (R&D): Lab 4 reported a sleep paralysis case from Trial B9. Again. Mira (QA Lead): Is it a repeat subject? Anderson (R&D): No. New participant. Same dosage. Mira (QA Lead): Looping the advisory board. We’ll need to adjust the intake profile.
[04/22/25 — 2:31PM] Dr. Ray (Medical Director): Received another pre-order request from an unverified clinic. This one from "Ark Station." Lena (Regulatory Affairs): That’s not in our registry. Flagged it for investigation.